The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels.
Prasugrel and clopidogrel are thienopyridines, require conversion to an active metabolite, and mediate an irreversible inhibition of the target receptor. Ticagrelor is a nonthienopyridine direct and reversible P2Y 12 platelet receptor antagonist and, unlike prasugrel or clopidogrel, concentration-dependently inhibits the sodium-independent equilibrative nucleoside transporter 1 (ENT1) (2) . This ticagrelor-mediated off-target effect has potential to increase adenosine levels, which may carry important clinical implications (2, 3) .
Increased adenosine levels in patients taking ticagrelor may explain some drug-specific side effects such as dyspnea and bradycardia or ventricular pauses (3) . In addition, the ticagrelor-mediated increase of adenosine levels might improve endothelial function (4), a possible barometer of the total atherosclerotic risk burden (5) and this effect may contribute to explain the reduced risk of mortality observed with ticagrelor as compared with clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) study.
There is limited and inconsistent evidence (6) (7) (8) that ticagrelor can increase adenosine plasma levels and subsequently improve endothelial function as compared with prasugrel and clopidogrel. We aimed to assess the effects of ticagrelor compared with other oral P2Y 12 inhibitors on the endothelial function, systemic adenosine plasma levels, and circulating vascular biomarkers at currently approved regimens in post-ACS patients. and exclusion criteria were previously reported (9) and are itemized in the Online Appendix. Eligible patients were those who suffered at least 30 days earlier from an ACS, were free from ischemic or bleeding complications, and reported regular intake of dual antiplatelet therapy regimen consisting of aspirin (80 to 160 mg daily) and a clinically indicated Ariotti et al.
The HI-TECH Trial finger plethysmography, as previously described (9) (Online Appendix). T ¼ ticagrelor.
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The HI-TECH Trial we set a mean RHI of 1.800 with a within-subjects SD of 0.31 (11) . With 36 patients completing all sequences (i.e., 6 patients/sequence) the study provided 90%
power to detect a 10% RHI relative change in the ticagrelor group (RHI after ticagrelor MD administration) with a 2-sided alpha level at 5%. A final sample size of at least 50 patients was targeted to account for dropouts and incomplete data assessment at all time points.
The primary endpoint only of the HI-TECH trial was previously reported (12) . In this paper, we report the full results of the trial including all secondary endpoints and predefined subgroup analyses.
STATISTICAL ANALYSIS. The primary endpoint was analyzed using repeated-measures 1-factorial ANOVA. The treatment factor had 3 levels: ticagrelor, prasugrel, or clopidogrel. The ANOVA yielded the differences between the 2 main comparisons:
ticagrelor RHI versus prasugrel RHI and ticagrelor RHI versus clopidogrel RHI. The significance of the 2 main comparisons was combined using the BenjaminiHochberg method to assess the primary endpoint.
FIGURE 2 Overview of Timing and Completeness of Study Procedures
Each line represents a patient. Days from index acute coronary syndrome to start of the first randomly allocated P2Y 12 inhibitor is shown on the left-hand side of the panel. For each P2Y 12 inhibitor sequence, duration and availability of reactive hyperemia index (RHI) assessment after the loading dose and before and after the maintenance dose is shown. For each patient, 3 (1 for each randomized P2Y 12 inhibitor) colored bars are typically shown. For each P2Y 12 sequence, the start of the colored bar shows when exactly the measurement was obtained after LD whereas the end of each colored bar shows when, before and after maintenance dose, the measurements were undertaken. After each colored bar, the white space shows the delay before the next randomized sequence was implemented. During these transitional periods, patients were kept on the P2Y 12 inhibitor allocated by the previous sequence (i.e., no wash-out periods). The caret (^) indicates patients included at Bern University Hospital who underwent flow-mediated dilation assessment, simultaneous to finger plethysmography evaluation. An asterisk (*) indicates that the patient did not complete C2 and C3 periods due to a skin allergic reaction to clopidogrel.
The HI-TECH Trial
The null hypothesis of randomized treatment equiv- Values are mean AE SD or n (%). *Defined as creatinine clearance <60 ml/kg/min. †Defined as atorvastatin 40 mg or greater or rosuvastatin 20 mg or greater.
ACE ¼ angiotensin-converting enzyme; ACS ¼ acute coronary syndrome; C ¼ clopidogrel; CABG ¼ coronary artery bypass grafting; NSTE-ACS ¼ non-ST-segment elevation acute coronary syndrome; P ¼ prasugrel; PCI ¼ percutaneous coronary intervention; T ¼ ticagrelor; TIA ¼ transient ischemic attack.
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RESULTS
A total of 54 patients were allocated to 1 of the 6 randomization sequences from December 17, 2015, to
October 25, 2016 (Online Figure 1 ). Of these, 50 (92.6%) patients completed the randomized P2Y 12 inhibitor sequence, and the primary endpoint measure was available for 47 (87.0%) (Figure 2 ).
The baseline features were similar across groups ( Figure 3 , Table 2 ). Results for the Values are n or median (interquartile range).
FMD ¼ flow-mediated dilation; PRU ¼ platelet reactivity units; RHI ¼ reactive hyperemia index.
The HI-TECH Trial primary endpoint were consistent across multiple subgroups (Online Figure 2) . There was no significant interaction between the primary endpoint and the randomized sequence (p ¼ 0.492).
ADENOSINE, PLATELET REACTIVITY, VASCULAR
BIOMARKERS, AND FMD ASSESSMENT. Systemic adenosine plasma levels did not differ after ticagrelor as compared with prasugrel or clopidogrel at any time point ( Figure 3 , Table 2 ). These results remained consistent at multiple subgroup analyses (Online Figure 3) . In ticagrelor-treated patients, there was no correlation between adenosine plasma levels and ticagrelor or AR-C124910XX levels. P2Y 12 platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points, and it was lower after MD, but not after LD as compared with prasugrel ( Figure 3 , Table 2 ). None of the vascular biomarkers differed after ticagrelor as compared with prasugrel or clopidogrel at any time point (Figures 3 and 4) . In a subset of 9 patients, FMD of the brachial artery was greater after the MD of ticagrelor (median 5.00%;
interquartile range: 4.20% to 6.60%) as compared with clopidogrel (median 3.20%; interquartile range:
1.98% to 4.35%; p ¼ 0.004), but not as compared with Ariotti et al.
The HI-TECH Trial The red dashed lines and boxes denote no difference in the effect of ticagrelor compared with prasugrel or clopidogrel. The green line and box indicate a higher effect of ticagrelor compared with prasugrel or clopidogrel. The yellow dotted line and box denote an unmeasured endpoint. C ¼ clopidogrel; P ¼ prasugrel; T ¼ ticagrelor.
The HI-TECH Trial affinity of ticagrelor for the ENT1 transporter (Ki ¼ 41 nmol/l) and the strong plasma protein binding, it was therefore anticipated that at clinically approved doses, ticagrelor could only partially inhibit ENT1 (2).
Circulating systemic plasma adenosine levels are very low in humans. However, it has been reported that they can increase locally at ischemic tissues (16) .
It was therefore suggested that ticagrelor can increase extracellular adenosine at tissue level through inhibition of ENT1 in erythrocytes and platelets, rather than increase systemic plasma levels (17). We did not find any measurable effect of ticagrelor on systemic adenosine plasma levels compared with the other oral ACS. However, despite not being randomly allocated, no effect of ticagrelor treatment versus other P2Y 12 inhibitors was noted even at baseline in our study.
Our findings do not confirm previous observations that ticagrelor increases systemic adenosine plasma levels and question the existence of a measurable ticagrelor's effect on endothelial function or vascular biomarkers in stabilized post-ACS patients at currently approved regimen.
CONCLUSIONS
We found no evidence that ticagrelor exerts measurable adenosine-mediated off-target effects on endothelial function at currently approved regimen in stabilized patients who suffered from an ACS. The HI-TECH Trial Ariotti et al.
